Amido-(propyl and allyl)-hydroxybenzamidines: Development of achiral inhibitors of factor Xa

Bioorganic and Medicinal Chemistry Letters

Volumn 10, Issue 3, 2000, Pages 217-221

  Gong, Yong ^a   Pauls, Henry W ^a   Spada, Alfred P ^a   Czekaj, Mark ^a   Liang, Guyan ^b   Chu, Valeria ^c   Colussi, Dennis J ^c   Brown, Karen D ^c   Gao, Jingbo ^c  

^a Rhone Poulenc Rorer PO B ^*  (United States)

^b NONE   (United States)

^c Cardiovascular Biology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDOALLYLHYDROXYBENZAMIDINE; AMIDOALLYLHYDROXYBENZAMIDINE 9J; AMIDOPROPYLHYDROXYBENZAMIDINE; BENZAMIDINE DERIVATIVE; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; SERINE PROTEINASE; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL MODIFICATION; CHIRALITY; DOG; DRUG DESIGN; DRUG INHIBITION; DRUG POTENCY; DRUG STRUCTURE; HUMAN; INHIBITION KINETICS; NONHUMAN; PARTIAL DRUG SYNTHESIS; RABBIT; RAT; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

ANIMALS; BENZAMIDINES; FACTOR XA; MODELS, MOLECULAR; MOLECULAR STRUCTURE; SERINE PROTEINASE INHIBITORS;

CANIS FAMILIARIS; MAMMALIA; ORYCTOLAGUS CUNICULUS;

EID: 0034614995     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(99)00673-3     Document Type: Article

References (32)

1. Davie E.W., Fujikawa K., Kisiel W. Biochemistry. 30:1991;10363.
2. Colman, R. W.; Marder, V. J.; Salzman, E. W.; Hirsh, J. Plasma Coagulation Factors. In Hemostasis and Thrombosis Basic Principles and Clinical Practice, 3rd Ed.; J. B. Lippincott: Philadelphia, 1994; pp 3-18.
3. Sanderson P.E.J., Naylor-Olsen A.M. Curr. Med. Chem. 5:1998;289.
4. Sturzebecher J., Hauptman J. Throm. Res. 93:1998;203.
5. Kaiser B., Hauptmann J. Cardiovasc. Drug Rev. 12:1994;225.
6. Ewing W.R., Pauls H.W., Spada A.P. Drugs of the Future. 24:1999;771.
7. Zhu B.-Y., Scarborough R.M. Curr. Opin. Cardiov. Pulmon. Ren. Investig. Drugs. 1:1999;63.
8. Al-Obeidi F., Ostrem J.A. Exp. Opin. Ther. Patents. 9:1999;931.
9. Scarborough R.M. J. Enz. Inhib. 14:1998;15.
10. Klein S.I., Czekaj M., Gardner C.J., Guertin K., Cheney D.L., Spada A.P., Bolton S.A., Brown K., Colussi D., Heran C.L., Morgan S.R., Leadley R.J., Dunwiddie C.T., Perrone M.H., Chu V. J. Med. Chem. 41:1998;437.
11. Czekaj, M.; Klein, S. I.; Gardner, C. J.; Guertin, K. R.; Zulli, A. L.; Pauls, H.; Spada, A. P.; Chu, V.; Brown, K.; Colussi, D.; Leadley, R. J.; Dunwiddie, C. T.; Morgan, S. R.; Heran, C. L.; Perrone, M. H.; Maignan, S.; Guilloteau, J. P.; Liang, G. Abstracts of Papers, 218th National Meeting of the American Chemical Society, New Orleans, LA, 22-26 Aug., 1999; American Chemical Society, Washington, DC, 1999; MEDI 32.
12. Related factor Xa inhibitors, with a similar motif, have also demonstrated an ester function dependence for optimal activity: Maduskuie, T. P. Jr.; McNamara, K. J.; Ru, Y.; Knabb, R. M.; Stouten, P. F. W. J. Med. Chem. 1998, 41, 53.
13. Fevig J.M., Cacciola J., Alexander R.S., Knabb R.M., Lam G.N., Wong P.C., Wexler R.R. Bioorg. Med. Chem. Lett. 8:1998;3143.
14. Sturzebecher J., Markwardt F., Walsmannn P. Thromb. Res. 9:1976;637.
15. Walsmann P. Acta Biol. Med. Germ. 36:1977;1931.
16. Philips G.B., Buckman B.O., Davey D.D., Eagen K.A., Guilford W.J., Hinchman J., Ho E., Koovakkat S., Liang A., Light D.R., Mohan R., Ng H.P., Post J.M., Shaw K.J., Smith D., Subramanayam B., Sullivan M.E., Trinh L., Vergona R., Walters J., White K., Whitlow M., Wu S., Xu W., Morrissey M.M. J. Med. Chem. 41:1998;3557.
17. Choi-Sledeski Y.M., McGarry D., Green D., Mason H., Becker M., Davis R., Ewing W.R., Dankulich W.P., Manetta V., Morris R.L., Spada A., Cheney D., Brown K., Colussi D., Chu V., Heran C.L., Morgan S., Bentley R., Leadley R., Maignan S., Guilloteau J.P., Dunwiddie C., Pauls H.W. J. Med. Chem. 42:1999;3572.
18. Ewing, W.R.; Choi, Y.M.; Becker, M.; Manetta, V.; Green, D.; Davis, R.; Mason, H.; Ly, C.; Cha, D.; McGarry, D.; Dankulich, W.P.; Spada, A.; Cheney, D.; Mason, J.; Brown, K.; Colussi, D.; Chu, V.; Bentley, R.; Morgan, S.; Heran, C.; Leadley, R.; Dunwiddie, C.; Perrone, M.; Pauls, H. Abstracts of Papers, 215th National Meeting of the American Chemical Society, Dallas, TX, 29 Mar.-2 Apr., 1998; American Chemical Society, Washington, DC, 1998; MEDI 203.
19. 1H NMR and MS: Klein, S. I.; Guertin, K. R.; Spada, A. P.; Pauls, H. W.; Gong, Y.; McGarry, D. G. PCT Int. Appl. WO9900356, 1999; Chem. Abstr. 1999, 130, 110161.
20. Vorbruggen, H.; Krolikiewicz, K. Synth. 1983, 316.
21. Francis J.E., Cash W.D., Barbaz B.S., Bernard P.S., Lovel R.A., Mazzenga G.C., Friedman R.C., Hyun J.L., Braunwalder A.F., Loo P.S., Bennett D.A. J. Med. Chem. 34:1991;281.
22. Ennis D.S., McManus J., Wood-Kaczmar W., Richardson J., Smith G.E., Carstairs A. Org. Proc. Res. Dev. 3:1999;248.
23. Poole, A. J.; Rose, F. L. J. Chem. Soc. 1971, 1285.
24. Dann, O.; Char, H.; Fleischmaan, P.; Fricke, H. Liebigs Ann. Chem. 1986, 438.
25. In vitro enzyme assays were run in triplicate as per: Bostwick, J. S.; Bentley, R.; Morgan, S.; Brown, K.; Chu, V.; Ewing, W. R.; Spada, A.; Pauls, H.; Perrone, M.; Dunwiddie, C. T.; Leadley, R. J. Thromb. Haemost. 1999, 81, 157.
26. In contrast no enhancement of activity was observed when representative β-aminoesters were substituted with para-hydroxybenzamidines:
27. The binding model was constructed with Chem-X/DiR and InsightII/Discover Software using the published X-ray structure: Tulinsky, A., Padmanbhan, K., Padmanbhan, K. P., Park, C. H., Bode, W., Huber, R., Blankenship, D. T., Cardin, A. D., Kiesel, W. J. Mol. Biol. 1993, 232, 947.
28. Maignan, S.; Guilloteau, J. P.; Mikol, V.; Choi-Sledeski, Y. M.; Becker, M.; Klein, S. I.; Ewing, W. R.; Pauls, H. W.; Spada, A. 218th National Meeting of the American Chemical Society, New Orleans, LA, Aug. 1999; American Chemical Society, Washington, DC, 1999; MEDI 20.
29. This biaryl P-4 unit has been used extensively by Dupont in their fXa inhibitors: Quan, M. L., Wityak, J., Dominguez, C., Duncia, J. V., Kettner, C. A., Ellis, C. D., Liauw, A. Y., Park, J. M., Santella, J. B., Knabb, R. M., Thoolen, M. J., Weber, P. C., Wexler, R. R. Bioorg. Med. Chem. Lett. 1997, 7, 1595.
30. Activated partial thromboplastin time (APTT) was measured with a MLA Electra 800 automatic coagulation timer (Orthodiagnostics, NJ) as described in reference 17.
31. Hara T., Yokoyama A., Morishima Y., Kunitada S. Thromb. Res. 80:1995;99.
32. Selected members from this series were found to be effective in animal models of thrombosis upon iv dosing; this data will be published separately.